JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $220 to $250.
JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $220 to $250.